Across TCGA pan-cancer cohorts, CD177 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD177 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD177 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD177 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where CD177 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.333	0.811	<.001	30	view →
PDAC	OS	Quartile	II,III,IV	0.621	0.981	.023	8	view →
HNSC	OS	Quartile	IV	1.000	0.702	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CD177 tumor-vs-normal RNA expression · all CD177 data types